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A B S T R A C T
Objective: Due to the immunomodulatory properties of mesenchymal stem cells (MSCs) through stimulation of
endogenous immune cells by paracrine signals and cell contact, they have been proposed as alternative treat-
ment option for many inflammatory and immune-mediated diseases in veterinary medicine. However, the long-
term cultivation possibilities of feline MSCs are currently compromised due to a restricted proliferation capacity.
Therefore, the xenogeneic use of equine peripheral blood-derived MSCs (ePB-MSCs) would present an interesting
alternative thanks to their superior cultivation properties. To the authors’ knowledge, there are currently no
safety reports concerning the xenogeneic use of ePB-MSCs in cats. Therefore, the overall goal of this preliminary
study was to investigate if ePB-MSCs can safely be administered in healthy cats and by extension evaluating their
immunogenic and immunomodulatory properties.
Methods: Ten healthy cats were intravenously (i.v.) injected with 3 × 105 ePB-MSCs at three time points (T0, T1,
T2). All cats were daily inspected by the caretaker and underwent a physical examination with hematological
and biochemical analysis at day 0 (T0), week 2 (T1), week 4 (T2) and week 6 (T3) by a veterinarian. Furthermore,
a modified mixed lymphocyte reaction (MLR) was performed at T0 and T3 for each cat in order to evaluate
immunogenic and immunomodulatory properties of the ePB-MSCs
Results: No adverse clinical effects could be detected following repeated i.v. administration of ePB-MSCs in all
cats. Significant lower protein (T1: P-value = 0.002; T2: P-value> 0.001; T3: P-value = 0.004) and albumin
levels (T1: P-value = 0.003; T2: P-value = 0.001) were seen after repeated administration of ePB-MSCs, com-
pared to T0. However, all biochemical and hematological parameters stayed within clinical acceptance level. In
addition, the repeated injections did not induce a cellular immune response before and after repeated ePB-MSCs
administration. Furthermore, convincing immunomodulatory properties of ePB-MSCs on feline peripheral blood
mononuclear cells were confirmed in the MLR-assay
Conclusion: This preliminary study demonstrates that ePB-MSCs can safely be administered in healthy cats and
provide a promising alternative for the treatment of various inflammatory diseases in cats.
1. Introduction
In recent years, mesenchymal stem cells (MSCs) have been proposed
as an alternative treatment for many inflammatory and immune-
mediated diseases in both human and veterinary medicine (Webb et al.,
2012). MSCs are plastic-adherent cells with high proliferation capacity
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which are able to differentiate in various mesenchymal cell types, in-
cluding osteocytes, chondrocytes, adipocytes and myocytes. Due to
their immunomodulatory properties, the use of MSCs has also been
focused on their ability to modulate inflammation rather than re-
generation of damaged tissues (Murray and Péault, 2015; Clark et al.,
2017).
In cats, the first isolation and characterization of bone marrow (BM)
derived MSCs was described in 2002, by Martin et al. Martin et al.
(2002) and were shown to present comparable phenotype and im-
munomodulatory profile to human MSCs (Clark et al., 2017). Although
BM represents an excellent source of MSCs, the invasive harvesting
process often requires anesthesia. Therefore, similar to other species,
less invasive tissue sources of MSCs have been investigated in cats.
Adipose tissue (Webb et al., 2012), fetal fluids and membranes (Iacono
et al., 2012) and peripheral blood (Sato et al., 2016), all showed similar
morphology to BM derived MSCs (Sato et al., 2016). However, the use
of feline autologous MSCs has proven to be difficult because up to 50 %
of the feline MSCs develop into giant foamy multinucleated cells in later
passages (from P5), leading to proliferation arrest. Arzi et al. (2015)
hypothesized this was due to an infection with the feline foamy virus
(FFV), which is present in 20–80 % of the cats without clinical signs
(Arzi et al., 2015). Next to this safety issue concerning the use of cell
lines with an active viral infection, autologous MSCs comprise the need
of harvesting tissue of an already compromised patient. Therefore, the
use of allogeneic MSCs derived from specific pathogen free (SPF) cats
presented a better option. Moreover, as in other veterinary species,
feline MSC quality declines with age (Zajic et al., 2017), so the use of
allogeneic MSCs allows a strict donor selection to ensure high quality
stem cells are being selected and can be used immediately “off-the-
shelf” (Quimby and Borjesson, 2018).
To date, the therapeutic use of allogeneic MSCs has shown pro-
mising results in several feline inflammatory diseases. In this regard,
the i.v. injection of allogeneic adipose-derived MSCs in cats diagnosed
with feline chronic gingivostomatitis (FCGS) has shown to result in
complete clinical and histological resolution or reduction in clinical
disease severity and immune modulation in most cats (Arzi et al.,
2017). Furthermore, the potential use of allogeneic MSCs as treatment
strategy for chronic kidney disease (CKD) has been investigated by
several research groups. Vidane et al. (2017) described a positive effect
on the symptoms and progression of CKD using allogeneic amniotic
membrane-derived MSCs (Vidane et al., 2017), however, other studies
using allogeneic adipose-derived MSCs did not support these findings
(Rosselli et al., 2016; Quimby et al., 2016). Pilot studies of Trzill et al.
(2015) and Webb et al. (2015) with repeated administration of allo-
geneic adipose-derived MSCs, have described promising results in the
treatment of asthmatic cats and chronic enteropathy, respectively (Trzil
et al., 2014; Webb and Webb, 2015). Finally, allogeneic adipose-de-
rived MSCs have been shown to be safe and effective in the treatment of
feline eosinophilic keratitis (Villatoro et al., 2018).
Nevertheless, the use of allogeneic feline MSCs is still restricted
because of their limited proliferation capacity compared to equine and
human MSCs and the financial and practical challenge of finding and
housing SPF cats (Clark et al., 2017; Arzi et al., 2017). Therefore, the
xenogeneic use of equine peripheral blood-derived MSCs (ePB-MSCs)
would present an interesting treatment alternative for above mentioned
diseases, as tissue harvesting from easily available healthy donor horses
provides an effective manner to produce MSCs. Furthermore, xeno-
geneic MSCs have the advantage of being free of transferrable highly
virulent species-specific pathogens. A recent study of Daems et al.
(2019) described already the feasibility and safe use of xenogeneic ePB-
MSCs in the treatment of naturally occurring osteoarthritis in dogs
(Daems et al., 2019). However, to the authors’ knowledge, there are
currently no safety reports concerning the xenogeneic use of ePB-MSCs
in cats.
The overall goal of this preliminary study was to investigate the
safety of repeated administrations of ePB-MSCs in healthy cats.
Therefore, effects on general physical condition and the hematological
parameters were evaluated. Furthermore, their immunogenicity and
immunomodulatory properties before and after multiple i.v. adminis-
trations were examined using a modified mixed lymphocyte reaction
(MLR) assay.
2. Materials & methods
2.1. Animals
This animal study was approved by the ethics committee of Global
Stem cell Technology (approval number EC: 2018_001, permit number:
LA1700607). All animal handlings were conducted according to
European, national and regional regulatory requirements and in com-
pliance with Directive 2010/63/EU. Ten healthy privately-owned cats
of different breeds (European shorthair, European longhair and Maine
Coon) were included in this study (mean age: 6± 4 years; 4 males, 6
females). The sample size was calculated based on previous MLR ex-
periments by our research group (data not published) using G*power
software, resulting in an effect size (f) = 2.86. Assuming α = 0.05 and
1-β = 0.95 a sample size of 9 was needed. Taking into account the
potentially loss of one blood sample a sample size of 10 cats was ne-
cessary for the safety evaluation. Blood samples of the cats were col-
lected by a licensed veterinarian and an informed consent was signed
by the owner. During the study, all cats stayed with the owner under its
care and protection.
2.2. Isolation and cultivation of equine peripheral blood-derived
mesenchymal stem cells (ePB-MSCs)
The ePB-MSCs were produced according to GMP-guidelines in a
GMP-certified site (number: BE/GMP/2018/123). They were isolated
from venous blood collected from the vena jugularis of one single donor
horse (approval number EC: EC_2012_001 and 2016_003) according to
previously described methods (Broeckx, 2012). Serum was tested on
multiple transmittable diseases by Böse laboratory before culturing
(Harsum, Germany). Subsequently, the ePB-MSCs were cultured until
passage (P)5 and thoroughly characterized (i.e. viability, morphology,
presence of cell surface markers, and population doubling times) as
previously described (Spaas et al., 2013), prior of being frozen as in-
termediate cell stock. After characterization, cells were thawed and
further cultivated until P10. Consequently, the ePB-MSCs were trypsi-
nized, resuspended at final concentration of 3 × 105 cells/mL in Dul-
becco’s Modified Eagle Medium (DMEM) low glucose with 10 % di-
methylsulfoxide (DMSO) and stored at −80 °C in cryovials until further
use. The ePB-MSCs were immunophenotypically characterized by
evaluating the presence (CD29, CD44 and CD90) and absence (MHC II
and CD45) of specific cell surface markers using flow cytometry as
previously described (Spaas et al., 2013). The cell viability was assessed
using trypan blue before freezing the cells. Sterility of the final product
was tested by the absence of aerobic bacteria, anaerobic bacteria, fungi,
endotoxins and mycoplasma.
2.3. Injection, general physical examination and hematology
All cats underwent a general physical examination by a veterinarian
at day 0 (T0), week 2 (T1), week 4 (T2) and week 6 (T3) consisting of the
assessment of rectal temperature, heart rate, respiratory rate, mucosal
membranes appearance and capillary refill time. At the same time,
blood samples (3 mL) were collected for hematological and biochemical
analysis. At T0 and T3, a larger blood volume (6 mL) was collected to
perform the MLR assay. At T0, T1 and T2, after the general physical
examination and blood collection, cats were intravenously (i.v.) in-
jected with 3 × 105 ePB-MSCs. After thawing the cryovial in the palm
of a hand, the content was checked for transparency and clearness and
the cell suspension was immediately injected using a 22 G i.v. catheter.
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After injection all cats were clinically monitored for any adverse events
(such as fever, increased respiratory rate, reduced feed uptake, vo-
miting, diarrhea or other signs of illness) by an experienced veter-
inarian for 30 min. Consequently, the cats were handed over to the
caretaker and were monitored on a daily basis. An adverse event form
was present for documenting adverse events and the veterinarian would
be contacted to discuss the plan of action.
2.4. Modified mixed lymphocyte reaction (MLR)-assay
The modified MLR assay was used to investigate whether or not the
ePB-MSCs induce a cellular immune response (immunogenicity) in the
cats and by extension to evaluate their immunomodulatory properties
by co-incubating the ePB-MSCs with stimulated responder peripheral
blood mononuclear cells (PBMCs). Therefore, a modified MLR assay
was performed using PBMCs isolated from the fresh blood of each cat at
T0 and T3.
For the MLR experiment, ePB-MSCs from the same batch as the ones
that were used for injection, were seeded at 2 × 104 MSCs/well in a 96-
well plate in a humidified incubator at 37 °C with 5 % CO2. PBMCs were
isolated from 6 mL venous blood from each cat and diluted with Hank’s
Balanced Salt Solution (HBSS). The diluted blood was layered on an
equal volume of Percoll and the interphase was collected after gradient
centrifugation. After washing the cells with HBSS, the PBMCs were
diluted in HBSS to a final concentration of 1 × 106 cells/mL.
Consequently, the PMBCs were labelled with carboxyfluorescein suc-
cinimidyl ester (CFSE) according to manufacturers instructions (CFSE,
Life Technologies) in order to evaluate cell proliferation. Finally, the
PBMCs were diluted in MLR medium (culture medium supplemented
with (fetal bovine serum (FBS), antibiotics/antimycotica (AB/AM) and
β-mercapto-ethanol (BME)) to a final concentration of 2 × 106 cells/
mL and 100 μL was added to the designated wells of the 96-well plate at
a ratio of 1:10 MSCs/PBMCs (= 2 × 104/2 × 105) to test the im-
munogenicity of the MSCs. Immunomodulatory properties of the ePB-
MSCs were assessed by co-incubating them with stimulated PBMCs. The
PBMCs stimulation was performed using concanavalin A (ConA, 5 μg/
mL, Sigma Aldrich). As positive control, PMBCs stimulated with ConA
without addition of ePB-MSCs were added to the 96-well plate. The
negative control sample consisted of PMBCs alone. Finally, the 96-well
plate was incubated for 4 days at 37 °C with 5 % CO2 containing MLR
medium.
After incubation, the PBMC proliferation (%) was measured using
flow cytometry analysis (BD FACSCanto II, BDbiosciences, US). All
samples were transferred from the 96-well plate to FACS tubes and
pelleted before staining for cell viability with 7-aminoactinomycine D
(7-AAD) at 1:100 (BioLegend, US). Viable PBMCs were gated on 7-AAD
after forward-, side scatter and double doublet discrimination.
Consequently, proliferation (%) of the viable PBMC population for
every FACS tube was evaluated using the CFSE staining.
2.5. Statistical analysis
In order to compare hematological and biochemical blood levels, a
mixed effects model with cat as random effect and time as categorical
fixed effects factor was used. Time points T1, T2 and T3 were compared
with time point T0 using Dunnett’s multiple comparisons technique. Log
transformed data were used for cell counts, and normal scale for others.
Significance level was set at 0.05. PBMC proliferation (%) was analyzed
using the non-parametric Wilcoxon signed rank test as data were not
normally distributed. A Bonferroni adjustment was applied to adjust for
multiple comparisons, setting the significance level at 0.05/3 =
0.0167.
3. Results
3.1. Physical examination and hematology
Based on the above described physical assessments, no abnormal-
ities could be noticed by the veterinarian or the caretaker of the cats
after the injection with ePB-MSCs at all time points (daily examination
or T1, T2 and T3). Furthermore, no adverse events related or unrelated
to the injections were reported during the study.
The effects of the i.v. injections with ePB-MSCs on the hematolo-
gical and biochemical parameters at each time point are summarized by
Table 1
Hematological and biochemical parameters at T0, T1,T2 and T3 together with their reference interval.
Parameter Unit Reference interval T0 (mean± SD) (min-max) T1 (mean± SD) (min-max) T2 (mean± SD) (min-max) T3 (mean± SD) (min-max)
Erythrocytes million/μL 5.00 – 10.00 8.38± 1.06 (5.96–10.63) 7.91± 1.20 (6.35–10.34) 8.12± 1.28 (6.62–10.41) 7.79± 1.08 (6.26–9.80)
Hemoglobin g/dL 8.3 – 17.3 12.0± 1.2 (7.8–14.6) 11.0± 1.6 (9.3–13.8) 11.2± 1.6 (9.5–14.4) 8.70± 0.44 (8.70–12.8)
Hematocrit % 27.0 – 47.0 37.6± 5.71 (23.0–49.3) 32.7± 4.8 (27.0–41.0) 33.6± 4.6 (29.0–43.0) 32.2± 4.4 (26.0–39.0)
MCV fL 39.0 – 55.0 45.2± 6.8 (36.4–61.5) 41.5± 2.7 (37.1–45.0) 41.6± 2.9 (36.7–46.8) 41.6± 3.4 (36.7–46.7)
MCH g/dL 12.0 – 18.0 14.4± 0.9 (12.3–15.6) 14.0± 1.0 (12.1–15.3) 13.9± 1.0 (12.3–15.4) 13.8± 1.0 (12.3–15.4)
MCHC g/dL 30.0 – 36.0 32.2± 3.4 (23.3–33.9) 33.8± 0.5 (32.8–34.4) 33.3± 0.3 (32.8–33.9) 33.2± 0.4 (32.8–33.8)








Neutrophil bars Abs. < 300 0 37±74 (0–229) 0 0
Neutrophil segments Abs. 2500 – 12500 5829±2663 (1624–11365) 5227±2445
(2799–10850)
5191±1217 (4248–8180) 4068±1340 (2530–6546)
Eosinophils Abs. < 1500 343±247 (81–748) 416±348 (96–1006) 512±625 (0–2148) 614±670 (0–2198)
Basophils Abs. < 100 0 0 0 0
Lymphocytes Abs. 1500 – 7000 4293±2113 (2031–8107) 3665±1552 (1947–5959) 3527±1330 (1513–6021) 3566±1279 (893–5700)
Monocytes Abs. < 850 224±111 (41–445) 185±138 (59–497) 253±160 (90–602) 157±93.3 (60.0–304)
Platelets x 1000/μL 180 – 430 304±182 (38–525) 338±182 (35–554) 414±157 (160–627) 297±188 (34–606)
Creatinine mg/dL 0.20 – 1.40 1.59± 0.36 (1–1.96) 1.43± 0.34 (0.96–1.97) 1.52± 0.28 (0.89–1.87) 1.37± 0.27 (0.91–1.67)
Urea mg/dL 40.0 – 70.0 52.6± 8.6 (43.2–64.7) 49.6± 10.4 (39.3–69.1) 51.0± 7.0 (40.4–60.1) 50.1–7.3 (40.3–63.5)
Total protein g/L 60 – 85 71±4 (64–76) 68± 3* (60–73) 67± 2* (64–70) 67± 3* (61–70)
Albumin g/L 23.6 – 46.6 33.7± 3.1 (26.4–39.3) 32.7± 3.6* (25.1–36.9) 32.4± 3.1* (25.9–36.5) 33.5± 4.0 (26.0–39.1)
Total bilirubin mg/dL <0.40 <0.15 <0.15 <0.15 <0.15
Bilirubin directly mg/dL <0.10 <0.10 <0.10 <0.10 <0.10
Bilirubin indirectly mg/dL <0.10 <0.10 <0.10 <0.10 <0.10
GOT (AST) U/L <83 43±13 (27–68) 30± 7 (19–39) 34± 11 (21–57) 27± 6 (19–37)
GPT (ALT) U/L <91 45±8 (31–68) 41± 9 (31–54) 48± 13 (33–70) 44± 18 (29–77)
Gamma-GT U/L <10 <3 <3 <3 <3
Alkaline phosphatase U/L 17 – 63 28±18 (5–69) 30± 14 (13–51) 30± 13 (14–48) 29± 15 (14–53)
*significant difference compared to T0 (P< 0.05).
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mean±SD and min-max values in Table 1. All parameter means were
within the reference interval except for the creatinine level. Mean
creatinine values were higher than the reference value (< 1.4 mg/dL)
at each time point during the study, however, creatinine values did not
increase significantly for any patient at all time point post-injection
compared to T0. When considering the individual values of all other
parameters, values were within clinically acceptable limits. Pairwise
comparisons showed that the total protein level was significantly lower
at T1 (p-value = 0.002), T2 (p-value>0.001) and T3 (p-value = 0.004)
compared to T0. Moreover, significant lower albumin levels were seen
at T1 (p-value = 0.003) and T2 (p-value = 0.001) compared to T0.
Other hematological and biochemical parameters did not change sig-
nificantly after i.v. injections with ePB-MSCs at T1, T2 and T3 (Table 1).
3.2. MLR assay
Individual results of the MLR assay are shown in Fig. 1 as PBMC
proliferation (%). Due to an extreme low number of events (< 1 × 103)
during the FACS analysis of the samples of one cat at T0, the results of
this particular cat were excluded from the data analysis for each time
point. Therefore, the results of the MLR assay were based on nine cats
instead of ten.
3.2.1. Immunogenicity
The addition of ePB-MSCs to feline PBMCs did not lead to a sig-
nificant increase in PBMC proliferation (median (min-max)) at T0 (1.4
% (0.5–11.5 %)) and T3 (2.3 % (1.6–8.5 %)) compared to the negative
control at T0 (2.2 % (1.0–9.3 %)) (p-value = 0.343) and T3 (5.6 %
(2.5–6.4 %)) (p-value = 0.05). For both time points, the co-culture of
ePB-MSCs and feline PBMCs was significantly lower than the associated
positive control at T0 (78.6 % (74.1–87.2 %)) (p-value = 0.008) and T3
(85.0 % (73.0–90.3 %)) (p-value = 0.008). Interestingly, when co-
culturing ePB-MSCs with feline PBMCs of cats who received three i.v.
injections with ePB-MSCs (T3) (2.3 % (1.6–8.5 %)), no significant in-
crease in mean proliferation could be seen compared to T0 (1.4 %
(0.5–11.5 %)) (p-value = 0.109) (Fig. 1).
3.2.2. Immunomodulatory
At T0, the proliferation of the co-culture of ePB-MSCs with stimu-
lated feline PBMCs was not significantly different compared to the as-
sociated negative control (2.2 % (1.0–9.3 %)) (p-value = 0.05). In
contrast, at T3 (27.7 % (11.5–41.2 %)) a significant difference was
found compared to the associated negative control (5.6 % (2.5–6.4 %))
(p-value = 0.008). Moreover, the proliferation of the co-culture was
significantly lower than the positive control at T0 (78.6 % (74.1–87.2
%)) (p-value = 0.008) and T3 (85 % (73.0–90.3 %) (p-value = 0.008)).
No significant difference in mean PMBC proliferation could be found in
the co-culture of ePB-MSCs with stimulated feline PBMCs at T3 (27.7 %
(11.5–41.2 %)) compared to T0 (14.6 % (0.6–32.4 %)) (p-value =
0.017) (Fig. 1).
4. Discussion
To the best of our knowledge, this is the first study to describe the
effects of repeated injections of equine PB-derived MSCs on the hema-
tological status of cats and to assess their immunogenicity and im-
munomodulation properties before and after repeated injections.
During the study all cats were in good health and at all time points
no adverse effects on their physical condition could be detected fol-
lowing the injections with ePB-MSCs. Furthermore, after communica-
tion with the caretaker of the cats, no adverse effects were noticed
during the entire study. Concerning the hematological and biochemical
parameters, all means of the blood parameters were within the re-
ference interval except for the mean creatinine levels, which were
higher than the reference interval at each time point. Nevertheless, this
mildly increased creatinine concentration was already present at
baseline condition (T0) and did not significantly increase for any cat at
all post-treatment time points. Therefore this could not be assigned to
the administration of the ePB-MSCs and was an existing abnormality in
the cat population. This could potentially be caused by dehydration or
an early stage renal insufficiency. However, because no clinical signs of
kidney problems were detected, we can assume this increase was not
clinically relevant. In order to improve determination of the feline renal
status and exclude potential chronic kidney disease, urinalysis and
Fig. 1. Mixed lymphocyte reaction (MLR) assay at T0 and T3. Individual PBMC proliferation (%) derived from 9 of the 10 cats (black dots) and median value (red
line). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).
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determination of serum symmetrical dimethylarginine (SDMA) could be
added in future studies.
Even though all other investigated parameters were within clini-
cally acceptance level, a significant decrease in total protein was found
at T1, T2 and T3, as well as for albumin levels at T1 and T2, compared to
T0. To the best of our knowledge, findings of lower protein and albumin
levels in blood after MSCs therapies have never been reported in cats.
However, these results were found in healthy cats and the impact of
ePB-MSCs on total protein and albumin levels in blood should be fur-
ther investigated in future studies using cats with different in-
flammatory diseases. Furthermore, a trend in lymphocyte decrease and
platelet increase could be seen at T1 and T2 compared to T0, but missed
significance due to high variability. The lymphocyte decrease is in line
with the in vitro immunomodulatory findings, which are also more
pronounced when lymphocytes are stimulated. Further research in
patients with increased lymphocyte levels should confirm this finding.
The platelet increase is in accordance with a previous reported study by
Broeckx et al. (2013) 24 h after a single injection with allogeneic ePB-
MSC in horses, and was assigned to bone marrow activation within the
acceptor horses after allogeneic ePB-MSC administration (Broeckx and
Forier, 2013). However, the current feline blood collection was per-
formed two weeks after each MSCs therapy and could explain why
significance was missed. Therefore, a blood collection 24 h post-injec-
tion of ePB-MSCs should be added in future feline studies. Overall, from
a clinical and hematological point of view, repeated injections (i.v) of
xenogeneic ePB-MSCs in cats can be considered safe and potentially
effective for patients with inflammatory diseases.
In the modified MLR assay, immunogenicity of the ePB-MSCs in cats
was tested using feline PBMCs derived before (T0) and after repeated
injections (T3). When co-culturing ePB-MSCs with feline PBMCs, no
cellular immune response was detected. This was demonstrated by a
comparable mean proliferation of the negative control sample. These
results clearly indicate that ePB-MSCs can be repeatedly injected
without inducing a cellular immune response.
Furthermore, various in vitro immunomodulatory properties of
MSCs have been described in literature, such as suppression of the
immune system and lymphocytes regulation (Kode et al., 2009).
Therefore, the immunomodulatory properties of ePB-MSCs on stimu-
lated feline PBMCs were also investigated. The co-culture of ePB-MSCs
with stimulated feline PBMCs resulted in a large immunosuppression
before and after repeated injections, which was demonstrated by a
significant lower mean proliferation of the co-culture compared to the
positive control at both time points. To date, numerous feline studies
have already demonstrated the immunomodulatory properties of both
autologous and allogeneic feline MSCs and showed similar im-
munomodulatory phenotype to human-, equine- and canine MSCs
(Clark et al., 2017; Zajic et al., 2017; Arzi et al., 2017; Parys et al.,
2017; Arzi et al., 2016). However, to the best of our knowledge, this is
the first study to describe the immunomodulatory properties of xeno-
geneic ePB-MSCs in cats after repeated injections. Results of the current
study showed superior immunomodulatory properties of xenogeneic
ePB-MSCs on feline PBMCs proliferation compared to previously re-
ported results with allogeneic feline MSCs (Clark et al., 2017; Zajic
et al., 2017). Clark et al. (2017) and Zajic et al. (2017) have reported a
median decrease in PBMC proliferation of 50 % (positive control (100
%) – co-culture (50 %)) and 47 % (100 % - 53 %), respectively, after co-
culturing stimulated feline PBMCs with the MSCs. In contrast, our study
showed a median decrease in PBMC proliferation of 64 % (79 % - 15 %)
at T0.
Their safe use, based on clinical and blood parameters, along with
the significant immunomodulatory properties, provides us with a strong
rationale for the xenogeneic use of ePB-MSCs in the treatment of var-
ious infectious diseases in cats and other species for that matter. This
would serve as a more efficient and potentially effective alternative
compared to the currently used allogeneic MSCs in cats. Nevertheless,
future studies using these ePB-MSCs in feline infectious diseases will
have to be performed to confirm their treatment efficacy.
In conclusion, to the authors’ knowledge, this is the first study to
evaluate the safety and immunomodulatory properties of xenogeneic
ePB-MSCs in cats before and after repeated administration. No adverse
clinical, hematological and biochemical effects could be detected. In
addition, the repeated injections did not induce a cellular immune re-
sponse. Furthermore, strong immunomodulatory properties of the xe-
nogeneic ePB-MSCs were confirmed in the MLR-assay. These promising
results prove that the xenogeneic use of ePB-MSCs in cats provides a
very interesting and cost-effective alternative for the treatment of var-
ious feline infectious diseases.
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